Deal-Making

Bayer plans $150m Californian biologics plant, creating 100 jobs

Bayer has teamed with GE Healthcare and Fluor to build a single-use clinical manufacturing plant in Berkeley, California to support its biologics pipeline. Plans have been laid for a 40,000 square-foot ‘Cell Culture Technology Center’ on Bayer’s existing Berkeley campus in California, set to begin production in 2021. The site already makes products including Bayer’s recombinant Factor VIII treatment for hemophilia A. At a cost of $150 million (€134 million), the new plant will “enable clinical and launch production of…

Alnylam: ‘Onpattro will springboard us into a global biopharma firm’

Alnylam says it is on course to becoming “a global multiproduct commercial biopharma company” by 2020 as sales of its messenger RNA interference therapeutic Onpattro (patisiran) begin to ramp-up. Alnylam Pharmaceuticals made history in August 2018 when Onpattro (patisiran), its product for the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, became the first small interfering ribonucleic acid (siRNA) treatment to be approved by the US Food and Drug Administration (FDA). Reporting its first quarter 2019 financials, the firm described the milestone…

Alector inks strategic deal with Lonza for early-phase candidates

The changing needs of biopharma have driven some customers towards more strategic development and manufacturing partnerships says Lonza, which has inked such a deal with Alector. The agreement, financials of which have not been divulged, sees biotech Alector secure manufacturing capacity for two of its Phase I neurodegeneration drug candidates at contract development and manufacturing organization (CDMO) Lonza’s site in Visp, Switzerland. Alector has seven immuno-neurology candidates in development. The deal makes use of Lonza’s Ibex Solutions service, launched in July…

Repligen to buy analytics firm C Technologies for $240m

Repligen Corporation will expand its bioprocessing services into the process analytics space through the acquisition of C Technologies. The deal, set to close in the next few weeks, sees Repligen add Bridgewater, New Jersey-based spectroscopy firm C Technologies to its bioprocess services. The $240 million (€214 million) deal is comprised of $192 million in cash plus $48 million in Repligen common stock. Repligen has focused over the last few years on broadening out its bioprocess portfolio. While it still boasts…

PureTech cites Big Pharma tech partnerships as 2018 highlights

PureTech Health says delivery technology deal with Roche was key part of its financial performance in 2018. The US biotech made the comments last week. It explained that its revenue growth for the year – $20.7 million (€18.5 million), up from $2.5 million in 2017 – was due in part to the Roche accord inked last July. CEO Daphne Zohar also predicted the deal will shape future performance. “We are now engaged in collaborative research with Roche to advance our…

Lilly inks potential $440m antibody oligo conjugate deal

Eli Lilly has teamed with Avidity Biosciences for the development of a new class of RNA-based drugs, antibody oligonucleotide conjugates (AOCs). The deal sees Big Biopharma firm Eli Lilly pay Avidity Biosciences $20 million (€18 million) upfront and invest a further $15 million into the L Jolla, California-based company. Depending on development, regulatory and commercialization milestones, Avidity could receive a further $405 million. Lilly hopes to use Avidity’s AOC tech platform to generate “new therapeutic targets in disease areas that…

Thermo Fisher allots $125m to expand CDMO buy Brammer

The gene therapy space is growing at an annual rate higher than 25% says Thermo Fisher, which recently agreed to buy CDMO Brammer Bio for $1.7 billion. Thermo Fisher announced last month the agreement to buy contract development and manufacturing organization (CDMO) for $1.7 billion (€1.5 billion), propelling the life sciences services firm into the gene therapy production space. While the deal has not yet closed (expected by end of Q2 2019), Thermo Fisher said on its first quarter financials…

Emerson buys Bio-G, adding modeling and scheduling software

Analytics and modeling tools can help deliver more effective and safer therapies to patients says Emerson, fresh from its acquisition of Bioproduction Group (Bio-G). Terms of the acquisition have not been divulged, but technology and engineering company Emerson extends its life sciences technology portfolio through the addition of Bio-G. “Many of biopharma’s biggest companies use Bio-G’s modeling and scheduling software for de-bottlenecking and optimization, and many of these same companies trust Emerson expertise and software to control their production and…

Catalent’s Paragon plans second plant to support Sarepta pipeline

Fresh from an acquisition agreement by Catalent, Paragon Bioservices is seeking to establish a second manufacturing plant dedicated to produce Sarepta Therapeutics’ gene therapy pipeline. Last week, contract development and manufacturing organization (CDMO) Catalent agreed to acquire gene therapy maker Paragon for $1.2 billion (€1.1 billion). Within hours of the announcement Paragon, with Catalent’s backing, said it is seeking to establish a second manufacturing facility at its site in Anne Arundel County, Maryland for the dedicated production of Sarepta gene…

Allele SCM partnership looks to stem cells to treat diabetes

Allele Biotechnology has teamed with SCM Lifescience to develop diabetes therapies using pancreatic beta cells derived from induced pluripotent stem cells (iPSCs). “By nature, pluripotent stem cells like iPSCs can be expanded indefinitely and differentiated into all human tissue types, including pancreatic cells,” a spokesperson from the San Diego-based biotech Allele, told Bioprocess Insider. Therefore, they can be a viable option for diabetes treatment. “iPSC-derived cells are already known to have biological functions, such as blood sugar sensing and insulin…